European shares set for eighth weekly gain; Hermes jumps after strong earnings By Reuters
Written by Emily J. Thompson, Senior Investment Analyst
Source: Investing.com
European Market Performance: European shares experienced a slight decline but are on track for their eighth consecutive week of gains, with the STOXX 600 index closing at record highs recently. Luxury stocks surged, particularly Hermes, which reported an 18% increase in fourth-quarter sales.
Sector Movements: While luxury goods companies saw significant gains, healthcare firms faced losses, notably Fresenius Medical Care, which dropped 6% following disappointing profit projections from U.S.-listed Dialysis DaVita.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVA is 136.50 USD with a low forecast of 130.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
0 Buy
3 Hold
1 Sell
Hold
Current: 109.170
Low
130.00
Averages
136.50
High
143.00
Current: 109.170
Low
130.00
Averages
136.50
High
143.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
